Everence Capital Management Inc. Boosts Holdings in Boston Scientific Co. (NYSE:BSX)

Everence Capital Management Inc. lifted its stake in Boston Scientific Co. (NYSE:BSX) by 4.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 42,890 shares of the medical equipment provider’s stock after purchasing an additional 1,680 shares during the period. Everence Capital Management Inc.’s holdings in Boston Scientific were worth $2,479,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of BSX. FMR LLC grew its position in Boston Scientific by 6.8% during the third quarter. FMR LLC now owns 125,920,357 shares of the medical equipment provider’s stock valued at $6,648,595,000 after buying an additional 8,045,263 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Boston Scientific by 1.2% in the third quarter. Vanguard Group Inc. now owns 123,768,348 shares of the medical equipment provider’s stock worth $6,534,969,000 after buying an additional 1,525,432 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Boston Scientific by 5.9% in the third quarter. Wellington Management Group LLP now owns 42,076,529 shares of the medical equipment provider’s stock worth $2,221,641,000 after buying an additional 2,336,348 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Boston Scientific by 1.9% in the first quarter. Geode Capital Management LLC now owns 25,329,129 shares of the medical equipment provider’s stock worth $1,263,857,000 after buying an additional 473,888 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in shares of Boston Scientific by 7.6% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 23,393,853 shares of the medical equipment provider’s stock worth $1,082,436,000 after buying an additional 1,659,431 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the completion of the transaction, the executive vice president now directly owns 56,508 shares of the company’s stock, valued at approximately $3,779,820.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $66.89, for a total value of $467,092.87. Following the transaction, the executive vice president now owns 56,508 shares in the company, valued at approximately $3,779,820.12. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Edward J. Ludwig sold 7,000 shares of the stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $65.03, for a total transaction of $455,210.00. Following the completion of the transaction, the director now owns 41,374 shares in the company, valued at approximately $2,690,551.22. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,979 shares of company stock valued at $3,418,529. 0.50% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several brokerages recently weighed in on BSX. TD Cowen boosted their price target on shares of Boston Scientific from $65.00 to $77.00 and gave the stock an “outperform” rating in a research report on Thursday, March 7th. Raymond James boosted their price target on shares of Boston Scientific from $67.00 to $73.00 and gave the stock a “strong-buy” rating in a research report on Thursday, February 1st. Evercore ISI boosted their price target on shares of Boston Scientific from $68.00 to $72.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Truist Financial boosted their price objective on shares of Boston Scientific from $59.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, December 22nd. Finally, Mizuho upgraded shares of Boston Scientific from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $65.00 to $80.00 in a research report on Thursday, February 1st. Two investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $68.50.

Boston Scientific Stock Up 1.0 %

NYSE:BSX traded up $0.68 during mid-day trading on Tuesday, reaching $68.12. The company’s stock had a trading volume of 6,622,890 shares, compared to its average volume of 6,378,311. Boston Scientific Co. has a 1 year low of $48.35 and a 1 year high of $69.21. The stock has a fifty day moving average of $67.05 and a 200-day moving average of $59.52. The firm has a market capitalization of $99.94 billion, a PE ratio of 63.03, a price-to-earnings-growth ratio of 2.38 and a beta of 0.78. The company has a quick ratio of 0.82, a current ratio of 1.32 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, January 31st. The medical equipment provider reported $0.55 EPS for the quarter, beating the consensus estimate of $0.51 by $0.04. The business had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.59 billion. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. During the same period in the prior year, the firm posted $0.45 earnings per share. Equities research analysts forecast that Boston Scientific Co. will post 2.25 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.